Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab versus LDL-C apheresis in severe hypercholesterolemia
2015-001343-37Phase 3Completed
- Sponsor
- Amgen
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of evolocumab in hypercholesterolemia (2 arms), sponsored by Amgen. Primary endpoint: Apheresis avoidance at end of randomized therapy. Started Nov 2015; status: completed.
02
Drugs
evolocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2015-001343-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001343-37.